Brenda Raud

I joined the group of John Haanen and the Amsterdam Biotherapeutics Unit (AmBTU) in April 2019 to research T cell immunology in human cancer and to contribute to the development and clinical application of novel cancer immunotherapies based on neoantigen-specific T cells.